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Abstract Glucagon-37 is secreted by intestinal L-cells following 
carbohydrate uptake. It is known to inhibit gastric acid secretion 
(hence also named oxyntomodulin) and appears to increase 
intracellular cyclic AMP concentrations. Since cyclic AMP 
could enhance intestinal glucose absorption, a possible stimula-
tory effect of glucagon-37 on glucose transport was examined. 
Glucagon-37 acutely increased glucose absorption in the isolated, 
vascularly perfused small intestine and in isolated enterocytes of 
the rat. In these cells the stimulation by glucagon-37 could be 
completely blocked by the cAMP antagonist Rp-cAMPS and 
was therefore mediated by cAMP. The stimulation of intestinal 
glucose absorption by glucagon-37 appears to be a major new 
physiological function. 
© 1997 Federation of European Biochemical Societies. 
Key words: Glucagon-37; Oxyntomodulin; Glucose 
absorption 
1. Introduction 
The glucagon gene is expressed in the A-cells of the endo-
crine pancreas and in the so called L-cells of the small intes-
tine. It encodes for a polyprotein of 160 amino acids, that is 
processed by limited proteolysis in a tissue-specific manner. In 
the A-cells the polyprotein is cleaved to yield pancreatic glu-
cagon-29 (amino acids 33-61), glucagon-related pancreatic 
polypeptide (GRPP) (amino acids 1-30) and the major pro-
glucagon fragment (amino acids 64-160); in the L-cells it is 
split to yield mainly enteric glucagon-37 (amino acids 33-69, 
i.e. glucagon extended by a C-terminal octapeptide), gluca-
gon-like peptide 1 (amino acids 72-108) and glucagon-like 
peptide 2 (amino acids 126-158) [1]. Pancreatic glucagon-29 
is released in the postabsorptive state; its major target tissue is 
the liver in which it has long been known to stimulate glyco-
genolysis and gluconeogenesis by a cyclic AMP-mediated 
mechanism in order to maintain glucose supply to the glu-
cose-dependent organs such as the brain and the erythrocytes. 
Enteric glucagon-37 is released in the postprandial, absorptive 
state; its major target tissue is the stomach in which it has 
been reported to antagonize the pentagastrin- or histamine-
stimulated acid secretion [hence its alternative name 'oxynto-
modulin'] at least partially through somatostatin release [2-A]. 
In the somatostatin-secreting cell line RIN-T3 glucagon-37 
stimulated somatostatin release, enhanced adenylate cyclase 
activity and increased cAMP [4]. 
In the small intestine glucose is absorbed via the sodium-
dependent glucose transporter 1 (SGLT1) at the apical, brush 
border membrane and the glucose transporter 2 (GLUT2) at 
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the basolateral membrane. It is generally believed that the 
process is controlled only by long-term adaptation of its ca-
pacity to metabolic changes such as lactation, pregnancy, dia-
betes mellitus or hypo- and hyperinsulinaemia rather than by 
short-term regulation of its activity [5-8]. However, there are 
some indications from work with freshly excised small intes-
tine, isolated enterocytes and brush border membrane vesicles 
that cAMP might acutely stimulate glucose absorption; yet 
the physiological stimulus triggering cAMP formation has re-
mained unknown [9]. Since enteric glucagon-37 is a hormone 
of the absorptive phase and may increase cAMP, it was the 
aim of the present study to evaluate whether it could acutely 
activate glucose absorption. Using the isolated perfused small 
intestine and villus tips enterocytes of the rat it was found that 
glucagon-37 indeed stimulated glucose absorption by a cyclic 
AMP-mediated mechanism. Thus, besides the stomach the 
small intestine appears to be another target organ for gluca-
gon-37. 
2. Materials and methods 
2.1. Materials 
All chemicals were of reagent grade and from commercial sources 
Enzymes were purchased from Boehringer (Mannheim, Germany), 
glucagon-37, dextran and bovine serum albumin from Appli Chem 
(Darmstadt, Germany), dibutyryl adenosine 3',5'-cyclic monophos-
phate from Sigma (Deisenhofen, Germany) and adenosine 3'-5'-cyclic 
monophosphothioate-Rp from Calbiochem-Novabiochem GmbFf 
(Bad Soden, Germany). 
2.2. Animals 
Male Wistar rats were obtained from Harlan-Winkelmann (Bor-
chen, Germany). They were subjected to a 12-h day-night rhythm 
with free access to food and water (standard diet of Ssniff, Soest, 
Germany). Preparation of the organ perfusion and isolation of enter-
ocytes were started at 9 a.m. Treatment of the animals was in accord-
ance with the German Law on Protection of Animals. 
2.3. Isolated, non-recirculating perfusion of the small bowel 
The operation followed the procedures described before for the 
joint perfusion of the isolated intestine and liver [10,11] with the ex-
ception that the liver was not included in the present experiments. In 
brief, rats (300-350 g) were anaesthetised by intraperitoneal injection 
of pentobarbital (60 mg/kg). The abdomen was opened and the supe-
rior mesenteric artery (SMA) and coeliac trunk (CT) were cannulated. 
Immediately afterwards the inferior vena cava (IVC) was opened by 
an incision and the non-recirculating perfusion of intestine was started 
at a hydrostatic pressure of 120 cmH20 and a total vascular perfusion 
rate of about 33 ml/min. Flow in the SMA was measured using a 
Transonic T 106 Flowmeter (Transonic Systems Inc., Ithaca, NY, 
USA). A catheter was introduced through the pylorus into the lumen 
of the duodenum and fixed. Following the incision of the coecum the 
intestinal content was washed out with a warmed saline solution. 
Afterwards the portal vein (PV) was cannulated for the vascular out-
flow and total vascular flow was quantitated by fractionating the 
effluate of the PV into calibrated tubes. Flow of the CT was defined 
as the difference between the flow in PV and SMA. At last the entire 
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intestine was prepared free from the body and transferred into an 
organ bath filled with a warmed saline solution. Experiments were 
started after a preperfusion period of 20 min. 
The intestinal lumen was not continuously perfused. A glucose bo-
lus of 1 g in 1.5 ml 0.9% NaCl was infused during a 1 min application 
period via the pyloric sphincter. Therefore, luminal flow and thus 
transit were due to a small net water secretion into the lumen and 
the physiological intestinal peristalsis. The time interval from applica-
tion of the carbohydrate bolus to appearance of the carbohydrate in 
the small intestinal effluate was taken as the transit time. 
The perfusion medium consisted of a Krebs-Henseleit buffer con-
taining 5 mM glucose, 2 mM lactate, 0.2 mM pyruvate, 1 mM glu-
tamine, 3% dextran and 1% bovine serum albumin, equilibrated with 
a gas mixture of 0 2 /C0 2 (19 : 1). Metabolites were measured using 
standard enzymatic techniques [10,11], 
2.4. Isolation of enterocytes 
Enterocytes were isolated by a standard low-temperature method 
[12]. Since the SGLT-1 is expressed mainly in mature enterocytes 
located on the villus tips, only these cells were used for the present 
investigations. In brief, the proximal one third of the small intestine of 
anaesthetised rats was removed and immediately washed with ice-cold 
Hanks' balanced salt solution (HBSS). It was everted, cut into small 
pieces and stirred on ice for 5 min in oxygenated HBSS containing 0.5 
mM dithiothreitol. The intestinal sheets were then transferred into 150 
ml of an oxygenated calcium-chelate buffer (27 mM Na3-citrate, 5 mM 
Na2HP04 , 96 mM NaCl, 8 mM KH 2P0 4 , 1.5 mM KCl, 20 mM D-
sorbitol, 20 mM sucrose, 2 mM glutamine, 1.5 mM dithiothreitol, 1 
mg/ml hyaluronidase) and stirred on ice for another 20 min. The 
separated enterocytes were collected by centrifugation (lOOOXg, 6 
min at 4°C) and washed twice in the incubation medium (80 mM 
NaCl, 100 mM mannitol, 20 mM Tris, 3 mM K 2HP0 4 , 1 mM MgCl2, 
2 mM glutamine, 1 mg/ml BSA, according to [13]). Viability of the 
cells was measured with the trypan blue exclusion method and was 
found to be greater than 90%. Cells were suspended in incubation 
medium to a final concentration of 2-106 cells-ml-1. Light microscopy 
and alkaline phosphatase activity were used to proof the purity of the 
villus tips enterocyte fraction since alkaline phosphatase activity is 
highest in the upper villus zone and almost absent in the crypts [14]. 
For carbohydrate transport studies 200 ul of the stock suspension 
of cells was distributed into several 20 ml glass flasks each containing 
100 ill incubation medium. The flasks were then incubated in a ther-
mostated water bath (37°C) with moderate shaking to ensure ad-
equate mixing and oxygenation of the cell suspensions. Following 
an incubation period of 10 min with or without effector substances 
the experiments were started by adding 0.6 uCi 14C-glucose (specific 
radioactivity 3.28 mCi-mmol-1; NEN, Bad Homburg, Germany) di-
luted in 100 ul incubation medium to a final glucose concentration of 
0.45 mM. The experiment in each vial was stopped after another 10 
min by quantitative transfer of the content onto a Whatman filter 
(Whatman, Maidstone, UK; pore size < 0.45 urn) placed on a frit-
ted-glass disk under negative pressure. The cell pellet, retained by the 
filter was washed with 10 ml of ice-cold incubation medium to remove 
radioactivity adhering to the cell surface. The filters were dried at 
100°C for 15 min and then directly transferred into scintillation fluid 
(LSC Hydroluma, Baker, Deventer, Netherlands) and counted for 
radioactivity. 
2.5. Statistical analysis 
All results are presented as means ± S.E.M. for the indicated num-
ber of observations. Data were analysed by Student's Mest for un-
paired data. Differences were considered significant at p < 0.05. 
3. Results 
3.1. Increase in intestinal glucose absorption by glucagon-37 in 
the isolated perfused small intestine 
Following the first glucose bolus into the intestinal lumen 
the portal glucose concentration as a result of intestinal glu-
cose absorption was increased from 4.9 ± 0.2 mmol/1 to a peak 
value of 6.7 ±0.3 mmol/1 (Fig. 1). Basal glucose absorption 
amounted to 706.2 ±72.6 |xmol or 12.8% of the applied bolus 
as indicated by the corresponding area under the portal glu-
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cose concentration curve (AUC 21.4 ±2.2 umol-ml-1-min) 
multiplied by the portal flow (33 ml-min-1) (Fig. 1). With 
infusion of glucagon-37 (final concentration in the perfusion 
medium 0.5 nM, a slightly supraphysiological concentration 
[2]) into the superior mesenteric artery (SMA) the portal glu-
cose concentration following the second glucose bolus was 
raised to a peak value of 10.8 ± 0.4 mmol/1. Thus, glucagon-
37 increased glucose absorption significantly by 3.3-fold to 
2369.4 ±481.8 umol or 43.1% of the applied bolus 
(AUC = 71.8 ±14.6 umol-mr1-min)-(flow = 33 ml-min"1) (p 
0.01). When as a control, the second glucose bolus was given 
without arterial infusion of glucagon-37 the maximum in-
crease in portal glucose concentration as well as the total 
amount of glucose absorbed were not different from glucose 
absorption following the first glucose bolus (Fig. 1). With 
infusion of glucagon-29 (final concentration in the perfusion 
medium 0.5 nM) there was no change in basal glucose absorp-
tion (data not shown). Lactate release by the small intestine 
during the entire experiment was at a very low, constant level 
and did not increase during infusion of glucagon-37 (data not 
shown). The vascular flow of the perfusion system remained 
essentially constant during the whole experimental period, i.e. 
it was not altered by glucagon-37 (Fig. 1). There was a mean 
small effluate from the intestinal lumen of about 0.31 ml/min, 
due to a net movement of water from the blood vessels to the 
lumen of less than 2% of vascular flow. This water movement, 
measured by fractionated sampling of the luminal outflow, 
was not altered by glucagon-37 (data not shown). The intes-
tinal transit time, i.e. motility, did not differ significantly be-
tween the first glucose bolus without and the second glucose 
bolus with glucagon-37 infusion (Fig. 1); it was 21 ±6 and 
23 ± 7 min, respectively. 
3.2. Stimulation by glucagon-37 of glucose uptake via cAMP in 
villus tips enterocytes 
In addition to the organ perfusion experiments the stimu-
latory effect of glucagon-37 on glucose transport was exam-
ined in isolated enterocytes. Cellular uptake of 14C-glucose 
(0.45 mM) was almost linear with time for 10 min; unstimu-
lated uptake of 14C-glucose amounted to about 70 pmol/106 
cells-min. Uptake in control experiments performed at 37°C 
was taken as 100%. Accumulation of 14C-glucose was cata-
lyzed by a specific transport system, since it was reduced to 
30% by addition of phlorizin (1 mM), an inhibitor of the 
intestinal brush-border glucose transporter SGLT-1 [15] and 
by low temperature incubation (4°C) (Fig. 2). Glucagon-37 
significantly stimulated 14C-glucose uptake into enterocytes 
to 220 ± 36% (p < 0.01). In an additional series of experiments 
with 14C-3-0-methyl-glucose, a glucose analogon which can 
not be metabolized, glucagon-37 stimulated glucose uptake 
into the enterocytes to a similar extent which excludes a po-
tential effect of glucagon-37 on glucose metabolism within the 
enterocytes (data not shown). In order to examine the puta-
tive involvement of cAMP in the glucagon-37 stimulated 
increase in glucose uptake, additional experiments were 
performed in the presence of a cAMP antagonist, the 
7?-stereoisomer of 3',5'-cyclic adenosine monophosphothi-
oate (Rp-cAMPS) [16]. Rp-cAMPS [10 uM] completely 
blocked the stimulatory action of glucagon-37 on enterocytic 
glucose uptake. In control experiments Rp-cAMPS alone did 
not show any influence on 14C-glucose uptake into the enter-
ocytes (Fig. 2). This clearly indicated that glucagon-37 
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Fig. 1. Increase by glucagon-37 in intestinal glucose absorption (upper panel) and constancy of flow rates and transit time (lower panel) in the 
isolated perfused small bowel of the rat. Following the intraluminal bolus infusion of 5.5 mmol glucose in the 6th minute glucose was absorbed 
as indicated by the increase in portal glucose concentration. From the 24th to the 35th minute of the experiment glucagon-37 (0.5 nM, Ggn-
37) was infused into the superior mesenteric artery (SMA). Glucose was applied again in the 25th minute. Values are means ± S.E.M. of 4 ex-
periments. Flow in the afferent SMA was measured by a flow meter and in the efferent portal vein (PV) by fractionated sampling. Flow in the 
coeliac trunk (CT) was the difference between SMA and PV flow. Transit time was the time interval from carbohydrate bolus infusion to ap-
pearance in the intestinal effluate. 
increased glucose absorption by a cAMP-dependent mecha-
nism. 
4. Discussion 
Glucagon-37 stimulated intestinal glucose absorption in iso-
lated perfused small intestine and in isolated enterocytes of 
the rat. This increase in glucose absorption was mediated by 
cAMP. 
4.1. Perfusion of the isolated rat intestine 
The vascularly perfused small intestine of the rat and the 
application of a sugar bolus have been used in several inves-
tigations to study intestinal carbohydrate absorption. Un-
stimulated intestinal glucose absorption and vascular flow 
rates of the present investigation were comparable with pre-
vious results [10,11,17,18]. The stable physiological function 
was monitored in each used organ preparation: (i) there was 
only little lactate release and no increase during the entire 
experiment indicating sufficient oxygen supply; (ii) flow in 
the CT and SMA did not decrease reflecting deterioration 
of the preparation due to tissue oedema or development of 
microembolisms [17,19]; (iii) intestinal motility was smooth 
and spastic contractions were absent. 
4.2. Stimulation by glucagon-37 of glucose absorption in the 
perfused small intestine 
Adaptations of the intestinal absorptive capacity to long-
term changes of the metabolic state have been demonstrated. 
Pregnancy [5], lactation [5], streptozotocin-induced diabetes 
mellitus [6], experimental hypo- and hyperinsulinaemia [7] 
and high-carbohydrate diets [8] in rats have been found to 
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Fig. 2. Increase by glucagon-37 and db-cAMP in glucose uptake 
and inhibition by Rp-cAMPS of the glucagon-37 stimulated uptake 
in isolated enterocytes. Enterocytes were isolated by a collagenase-
free chelate buffer and then incubated in single glass flasks in a 
thermostated water bath (37°C, except for analysis of temperature 
dependency [Temp] at 4°C). In the controls no effector was added 
and 14C-glucose uptake was taken as 100%. Phlorizin (1 mM, 
Phlor), Rp-cAMPS (10 uM), glucagon-37 (1 nM, Ggn-37), db-
cAMP (10 uM, cAMP) and glucagon-37 plus Rp-cAMPS (10 u.M, 
Ggn-37+RpcAMPS) were given 10 min prior to starting the experi-
ments by adding 0.45 mM 14C-glucose (0.6 uCi) into the flasks. The 
experiments were stopped by quantitative transfer of the content 
onto a Whatman filter and the retained cell pellet counted for radio-
activity. *p<0.01 vs. Contr; +/J < 0.01 vs. Ggn 37. Data represent 
the means ± S.E.M. of 4—5 experiments, each. 
increase intestinal glucose absorption; the underlying mecha-
nism was an alteration in the number of intestinal glucose 
transporters. However, the rapid onset of the increase in glu-
cose absorption in the present investigation (Fig. 1) excludes 
the possibility of enhancing the carbohydrate absorption by 
de-novo synthesis of intestinal glucose transporters. 
The increase in intestinal carbohydrate absorption could 
have been caused by three other general unspecific mecha-
nisms: changes in total vascular perfusion rate, changes in 
effective mucosal flow due to an intestinal redistribution of 
total flow and changes in intestinal motility. However, there 
was no change in the total vascular flow nor in SMA and CT 
flow (Fig. 1). Also, an undetected redistribution of total flow 
within the intestinal mucosa is unlikely to have occurred since 
effects of glucagon-37 on vascular flow rates have not been 
described so far. Intestinal motility, as measured by the transit 
time of a glucose load, was not significantly altered by gluca-
gon-37 (Fig. 1). In conclusion, general unspecific mechanisms 
are unlikely to explain the increase by glucagon-37 of intesti-
nal absorption of glucose. A specific stimulation by glucagon-
37 of intestinal glucose absorption must be considered. 
4.3. Stimulation by glucagon-37 of glucose uptake into 
enterocytes 
Enteric glucagon-37 and pancreatic glucagon-29 have been 
shown to increase intracellular cAMP concentrations in intact 
RIN T3 cells (a somatostatin secreting cell line) and to stim-
ulate adenylate cyclase activity in RIN T3 cell membranes; 
glucagon-37 was 10-30 times more potent than glucagon-29 
[4]. The two hormones stimulated adenylate cyclase activity 
also in rat liver plasma membranes, however, conversely glu-
cagon-37 was less potent than pancreatic glucagon-29 [20]. 
Moreover, in isolated oxyntic glands of the rat glucagon-37 
increased the intracellular cAMP concentration with a 20-fold 
higher potency than glucagon-29 [21]. Finally, [125I]glucagon-
37 had a 10-fold higher binding affinity to RIN T3 cell mem-
branes than [125I]glucagon-29 [4,22]. Apparently, glucagon-37 
increases cAMP after binding to a specific receptor. The 
present finding that the stimulatory action of glucagon-37 
on 14C-glucose uptake into isolated enterocytes could be com-
pletely prevented with the cAMP antagonist Rp-cAMPS and 
was therefore mediated by an increase in intracellular cAMP 
concentrations, is in line with expectations. 
The cAMP-mediated action of glucagon-37 on isolated en-
terocytes shows that its effects in the perfused intestine were 
specific. The involvement of cAMP is in accordance with pre-
vious observations: In mice lacking the cAMP-stimulated Cl~ 
secretion due to targeted gene disruption, a cAMP-stimulated, 
glucose-dependent increase in Na + absorption could be de-
tected under voltage-clamp conditions [23]. In the human rec-
tal adenocarcinoma cell line HRT-18 under basal conditions 
no glucose-dependent electrogenic Na+ movement could be 
measured; however, following cAMP a short circuit current 
was detected that was glucose-dependent [24]. In brush border 
membrane vesicles cAMP moderately enhanced glucose up-
take by 30% and in the brush border membrane it slightly 
increased the membrane potential by 10 mV [9]. 
4.4. A new function for glucagon-37 
So far, the major role for glucagon-37 in short-term regu-
lation was the inhibition of gastric acid secretion [3]. In the 
present study evidence for a new role of glucagon-37 in short-
term regulation is presented: Since enteric glucagon-37 was 
found to be secreted in the absorptive state following food 
intake in man [25] and in rats [2], its acute stimulation of 
intestinal glucose absorption could be a major physiological 
function. This action is clearly different from that of pancre-
atic glucagon which in the postabsorptive state stimulates 
hepatic glucose release. 
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